The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is now priced at $16.86 and the shares are 0.81 points up or 5.05% higher compared to its previous closing price of $16.05. The stock had 2.082 million contracts set over the past session. KPTI shares’ daily volume is compared to its average trading volume at 1.887 million shares. However, it has a float of 66.07 million and although its performance was -5.55% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the KPTI share price recently placing at $16.16 to $17.13. However, some brokerage firms have priced the stock below the average, including one that has called $26.
The shorts are climbing into the Karyopharm Therapeutics Inc. stock, with the latest data on short interest released on July 15, 2020, showing that short interest numbers in the KPTI shares have risen. Short interest in the stock represents just 25.27% of its float, but the volume has raised by 1116215. The volume of shorted shares rised to 16.695 million from 15.579 million shares over the last two weeks. The average intraday trading volume has been 1.591 million shares, which means that days to cover moved to roughly 10.494422.
In the last trading session, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) dropped by -$0.99 over the week and lost -$2.71 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $29.61. The stock recorded its established 52-week high on 03/02/20.
Since 08/06/19, the stock has traded to a low of $7.55 at 123.31%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 1.46. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, Karyopharm Therapeutics Inc.’s two-week RSI is 41.12. This suggests that the stock is neutral at the moment and that KPTI shares’ price movement remains stable. The stochastic readings are equally revealing at 11.75% meaning the KPTI share price is currently in overbought territory.
The technical chart shows that the KPTI stock will likely settle at between $17.27 and $17.69 per share. However, if the stock dips below $16.3, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $15.75.
Currently, the stock is trading in the red of MACD, with a reading of -0.96. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned KPTI a rating of Overweight in their intiating review released on July 02. Barclays analysts see the stock as a Overweight with a target price of $30 in a flash note released to investors on March 04 initiating covering the stock. Wedbush seeing the stock struggling downgraded it from Outperform to Neutral on January 17.
The average rating for the KPTI equity is 1.67 and is currently gathering a bullish momentum. Of 10 analysts tracking Karyopharm Therapeutics Inc. polled by Reuters, 1 rated KPTI as a hold. The remaining 9 analysts were split evenly. However, the split wasn’t equal as a majority (9) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Elsewhere, the KPTI stock price is 0X ahead of its 12-month Consensus earnings per share estimates.
Zacks Consensus Estimate forecasts that the current-quarter revenues for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) will decrease by about -99.85%, which will see them reach $27.42 million. The company’s full-year revenues are, however, expected to increase by about 158.69%, up from $40.89 million to $105.78 million. KPTI’s expected adjusted earnings should drop almost -18.31% to end up at -$0.58 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -23.29% to record -$2.47/share.